Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206934 | 1.00 | CCR1 (0.64) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL10287870 | 0.95 | CCR1 (0.66) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL14419959 | 0.94 | CCR1 (0.66) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL13824477 | 0.94 | CCR1 (0.66) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL13824314 | 0.93 | CCR1 (0.63) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL12121890 | 0.92 | CCR1 (0.54) | CCR1CHRM2CCR5DRD2 | |
| SCHEMBL10287601 | 0.91 | CCR1 (0.63) | CCR1CHRM2CCR5DRD2 | |
| SCHEMBL10288263 | 0.91 | CCR1 (0.63) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL18895949 | 0.91 | CCR1 (0.65) | CCR1CHRM2CCR5DRD2OPRM1 | |
| SCHEMBL7205645 | 0.91 | CCR1 (0.61) | CCR1CHRM2CCR5DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613905-B1 | Treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |